High performance low dielectric polybenzocyclobutene nanocomposites with organic-inorganic hybrid silicon nanoparticles.

In this study, benzocyclobutene-functionalized organic-inorganic hybrid spherical silicon nanoparticles (BCBNPs) with controllable size (200-600 nm) and good dispersion were synthesized by a one-step sol-gel method in aqueous solution. The effect of the reaction conditions (time, precursor concentration, pH value and temperature) on the particle size of the BCBNPs and the formation mechanism of the BCBNPs were studied. What is more, homogeneously dispersed BCBNPs/divinyltetramethyldisiloxane-bis(benzocyclobutene) (BCBNPs/PDVSBCB) nanocomposites were prepared and the influence of the incorporation of BCBNPs on the properties of the nanocomposites was investigated. The dielectric constants of the BCBNPs/PDVSBCB nanocomposites were drastically reduced relative to neat PDVSBCB, and were as low as 2.25 (30 MHz). Besides, the thermal and mechanical properties of the BCBNPs/PDVSBCB nanocomposites were significantly improved, evidencing their potential applications in the field of high-performance dielectric materials.

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma.

Angiogenesis is initiated by the activation of the vascular epidermal growth factor receptor-2 (VEGFR-2) by the vascular epidermal growth factor (VEGF) ligand. Overexpression of VEGFR-2 increases the growth of nasopharyngeal carcinomas (NPC). Apatinib (YN968D1) is a highly-selective inhibitor of VEGFR-2, but its effects on NPC have not been hitherto investigated. In the present study, CNE-2 NPC cells were xenografted into 132 nude mice, which were treated with one of 6 drug regimens of apatinib administered alone or in combination with cisplatin (DDP). The impact of treatment regimens on the growth, microvascularization, apoptosis, and metabolic response of tumors, as well as mouse survival was determined by histopathology, immunohistochemistry (VEGFR-2 and CD31), terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL), micro 18F-FDG PET/CT imaging and survival curves. Administration of apatinib alone inhibited tumor growth, reduced microvascular density, and facilitated the apoptosis of tumors. Tumors treated simultaneously with apatinib and cisplatin exhibited significantly-increased inhibition of tumor growth, prolonged survival time, decreased expression of VEGFR-2, reduced microvascular density, and frequency of apoptosis over standalone and sequential administration therapy. Tumors treated simultaneously with apatinib and cisplatin had the lowest uptake of FDG. Taken together, the simultaneous administration of apatinib and cisplatin improves the therapeutic efficacy over standalone treatments, which also led to improved efficacy over sequential administration regimens. VEGFR-2 is an important predictive marker for efficacy of apatinib treatment of NPC.